What is the main business of Pharmalogics?

The main business activity of Pharmalogics focuses on other professional, scientific and technical activities not elsewhere classified.

When was the company founded?

The company was registered in the Polish National Court Register (KRS) on March 1, 2024.

Where is the headquarters located?

The headquarters is located at: ul. Nowogrodzka 50/54, 00-695 Warszawa.

What is the share capital?

The share capital of the company is PLN 5,000 (approx. $1,351).

What period do the latest financial data cover?

The latest available financial statement covers the period from January 1, 2025 to December 31, 2025.

What was the revenue?

The company reported a revenue of $540,259 in 2025, which is an increase of 114.2% compared to 2024.

Is the company profitable?

Yes, the company recorded a net profit of $129,043 in 2025, representing a multi-fold increase compared to 2024.

Which cost dominates operating expenses?

The largest operating cost category falls under external services. This category amounted to $287,827 in 2025, representing 72% of all operating expenses.

Pharmalogicssp. z o.o.

Other professional, scientific and technical activities not elsewhere classified

KRS: NIP: REGON:

Overview

Status

Active

Registry date

2024-03-01

Share capital

5,000.00 PLN

Activity description

Pharmalogics provides comprehensive, specialist support to pharmaceutical companies. Its team of experts has many years of experience.

Registered address

ul. Nowogrodzka 50/54/515, 00-695 Warszawa, Poland

Website

pharmalogics.pl

Phone

Electronic delivery address

AE:PL-17379-61498-FTABB-28

Financials

Revenue history (in k)

Filing timeliness

Financial statements were filed on time, on average 117 days early.

202513/03/2026
202427/03/2025

Filed on timeDelayFiling deadline

Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.

Statistics

How the company ranks by revenue within its industry, region and across Poland in 2025.

Results vs industry

Revenue

This companyUSD 540.26kMedianUSD 70.54kAverageUSD 519.25k

Net profit

This companyUSD 129.04kMedianUSD 2.53kAverageUSD 5.54k

Operating costs

This companyUSD 397.72kMedianUSD 57.18kAverageUSD 450.21k

Assets

This companyUSD 166.90kMedianUSD 61.01kAverageUSD 1.39m

Industry

Offer

Preparation of drug registration documentation
Medical documentation audits
Regulatory consulting
Toxicological analyses
Clinical trial support
Clinical evaluation reports for medical devices
Medical representative training

Authorized Representatives

Mateusz Gołąb – President of the Management Board

Manner of representation

Each member of the management board is independently entitled to make declarations on behalf of the company.

Ownership

Owner	Shares	Share value	Stake
Mateusz Gołąbage 45	90	$1,215.56	90%
Urszula Natalia Skalskaage 42	10	$135.06	10%

Beneficial owners

Person	Rights

Bank accounts

Registered as a VAT taxpayer on 2024-03-08.

Bank Millennium
84 1160 2202 0000 0006 0525 8049
Bank Millennium
90 1160 2202 0000 0006 0525 2897

Debt

No entries in the National Debtors Register (KRZ).

Public aid

No public aid cases recorded in the last 10 years.

Competitors

Name	Revenue	Website
Neupharmsp. z o.o.	$4,870,126.36	neupharm.com.pl
Kontekst A. Wolskisp. k.	$1,649,677.25	kontekst.com
Pro4biznessp. z o.o.	$54,553.45	pro4biznes.pl

FAQ

Last updated: 2026-04-08